Why the Resapp (ASX:RAP) share price stormed 5% higher today

The Resapp Health Ltd (ASX: RAP) share price stormed 5.8% higher today following an announcement of a new partnership.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Resapp Health Ltd (ASX: RAP) share price stormed higher today following the announcement of a new partnership.

During afternoon trade, shares in the digital health company reached as high as 9.4 cents, but later pulled back slightly. The ResApp share price closed out the day at 9.1 cents, up 5.8%.

Let's take a look at what ResApp updated the market with.

Integration of ResAppDx

According to the release, Resapp advised that it has entered a six-month joint development and pilot agreement with Medgate. The new deal will see Medgate use Resapp's smartphone-based acute respiratory diagnostic test, ResAppDx, in its telemedicine services.

Founded in 1999, Medgate is a provider of telehealth services, bringing physicians to where patients are needed via digital health bookings. The company operates Europe's largest telemedical centre in Switzerland, employing over 500 people worldwide. Medgate has presence in Germany, the Philippines, the United Arab Emirates, and India.

Under the agreement, Medgate and Resapp will work together to build and pilot an integration of ResAppDx in Medgate's services. The integration phase of the project is expected to take around two months. Thereafter, a three-month pilot will commence in early 2021, evaluating the performance of the new program.

During the initial stages, both companies will assess the impact that ResAppDx has on Medigate's telehealth service. A number of key metrics will be applied as a benchmark to test its success.

Negotiations on the cost model of the integration will be finalised during the pilot period.

Resapp advised it will not see material revenue from the project. Either party may terminate the contract by providing 30 days notice.

What did management say?

Resapp CEO and managing director Mr Tony Keating commented on the partnership:

We are very pleased to have entered into this pilot agreement with such a high calibre partner. Medgate is a well-known and respected organisation and we look forward to working with them to deliver our ResAppDx product to their customers.

This partnership is ongoing validation of our offering and will potentially allow the company to pursue a large market opportunity in Europe, as well as in Asia and the Middle East where Medgate also has operations. I look forward to updating shareholders on the integration and commencement of the pilot initiative in the coming months.

Resapp share price summary

The Resapp share price has taken a hit over the last few weeks since revealing its quarterly earnings scorecard. Shares in the company fell to a 7-month low of 8.2 cents, but have since slightly recovered.

No doubt, today's announcement has had a positive effect on the Resapp share price, however it still has some way to go to hit its former highs of 50 cents, reached back in September 2016.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 20% to 100%

Analysts are expecting these shares to deliver big returns over the next 12 months.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares finished the trading week on a high this Friday.

Read more »

A businessman stacks building blocks.
Technology Shares

6% gain! What's up with Block shares today?

Block shares are up more than 34% since 2 May.

Read more »

Broker looking at the share price.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today

These shares are having a strong finish to the week. But why?

Read more »

A woman puts her hands up as she smashes and breaks through a glass ceiling.
Share Gainers

How these 5 ASX 200 stocks are smashing the benchmark this week

These fives ASX 200 stocks have made some very happy shareholders this week. Here’s how.

Read more »

Bored man sitting at his desk with his laptop.
Share Fallers

Why Catalyst Metals, Duratec, Nufarm, and Rio Tinto shares are dropping today

These shares are ending the week in the red. But why?

Read more »